InspireMD, Inc.
No enriched coverage for $NSPR in the last 7 days.
No SEC Form 4 filings for $NSPR in the last 30 days.
See all $NSPR insider activity →InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.
InspireMD reported Q2 2026 results, citing flat revenue from a voluntary recall of its CGuard Prime 135 delivery system. Management said $734,000 in customer credits offset underlying U.S. growth, with a $612,000 inventory impairment and negative reported gross margin of 43.7%. It cut staff 20% and expects about $9M annual savings. FDA decisions for CGuard Prime 80 (TCAR) and CGuard CAS are targeted for Q4 2026, with Prime 135 reentry in H1 2027.
InspireMD (NSPR) reported Q2 2026 revenue of $1.8M, flat year over year, as international sales rose 21% to $2.1M but U.S. revenue fell to -$0.4M due to a voluntary recall and $0.7M in customer credits. Net loss was $14.3M ($0.17/share). The company is redesigning CGuard Prime 135 cm for FDA submission and expects U.S. relaunch pending approval.
Recent NSPR coverage spans earnings, corporate actions and financial news.
Earnings miss and recall charge pressure the stock, but loss per share beat and cost‑saving plan may limit downside.
InspireMD reported Q2 2026 results, citing flat revenue from a voluntary recall of its CGuard Prime 135 delivery system. Management said $734,000 in customer credits offset underlying U.S. growth, with a $612,000 inventory impairment and negative reported gross margin of 43.7%. It cut staff 20% and expects about $9M annual savings. FDA decisions for CGuard Prime 80 (TCAR) and CGuard CAS are targeted for Q4 2026, with Prime 135 reentry in H1 2027.
Near-term sentiment is likely driven by recall-related revenue/credit impacts and gross loss widening, while the relaunch and FDA submission timeline provide a forward catalyst.
The filing updates near-term risk around the CGuard Prime U.S. recall, cash runway, and timing of FDA submissions for both TCAR and CAS delivery systems.
Board/officer change signals potential commercial strategy reset and near-term execution risk, but no financial guidance or deal terms were provided.
alphai scores every news story that mentions NSPR with an AI model for sentiment and relevance, and aggregates insider trades from InspireMD, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.
2 min readInspireMD reported Q2 2026 results, citing flat revenue from a voluntary recall of its CGuard Prime 135 delivery system. Management said $734,000 in customer credits offset underlying U.S. growth, with a $612,000 inventory impairment and negative reported gross margin of 43.7%. It cut staff 20% and expects about $9M annual savings. FDA decisions for CGuard Prime 80 (TCAR) and CGuard CAS are targeted for Q4 2026, with Prime 135 reentry in H1 2027.
6 min readInspireMD (NSPR) reported Q2 2026 revenue of $1.8M, flat year over year, as international sales rose 21% to $2.1M but U.S. revenue fell to -$0.4M due to a voluntary recall and $0.7M in customer credits. Net loss was $14.3M ($0.17/share). The company is redesigning CGuard Prime 135 cm for FDA submission and expects U.S. relaunch pending approval.
6 min readInspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - Miami, FL — August 17, 2026 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carot
6 min readInspireMD, Inc. (NSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 23, 2026, InspireMD, Inc. (the “Company”) provided notice to Shane Gleason, the Company’s Chief Commercial Officer
2 min readInspireMD, Inc. (NSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001433607 0001433607 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
3 min readInspireMD (Nasdaq: NSPR) said its Compensation Committee approved inducement grants for six new non-executive employees totaling 91,161 shares of restricted stock, dated June 12, 2026, under Nasdaq Rule 5635(c)(4). The awards are under the 2024 Inducement Plan and vest over three years, subject to continued employment.
2 min readInspireMD (Nasdaq: NSPR) reported 30-day results from its CGUARDIANS II trial of the CGuard Prime 80 cm implant for TCAR. In 50 high-risk patients, acute device success was 100% (50/50) with no deaths, strokes, MI, or stent thrombosis at 30 days. The company said an FDA PMA supplement is under review, with potential approval in H2 2026.
5 min readStuka Paul purchased 20,000 shares of InspireMD, Inc. (NSPR) at $0.88 on 2026-05-27.
1 min readInspireMD director Paul Stuka purchased 75,626 shares of the company's common stock through open-market transactions on May 8 and May 11, 2026. These buys, totaling approximately $88,026, increased his direct beneficial ownership to 632,871 shares. The report also clarified previous ownership figures, noting a correction from an August 2025 filing regarding shares held directly versus indirectly through Osiris Investment Partners, L.P.
2 min read
